Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression

被引:21
作者
Hennrich, Ute [1 ]
Seyler, Lisa [1 ]
Schaefer, Martin [2 ]
Bauder-Wuest, Ulrike [2 ]
Eisenhut, Michael [2 ]
Semmler, Wolfhard [1 ]
Baeuerle, Tobias [1 ]
机构
[1] DKFZ, Dept Med Phys Radiol, D-69120 Heidelberg, Germany
[2] DKFZ, Dept Radiopharmaceut Chem, D-69120 Heidelberg, Germany
关键词
Molecular imaging; CXCR4; PET; Gallium-68; HUMAN CANCER XENOGRAFTS; CHEMOKINE RECEPTOR; N-SUCCINIMIDYL; T140; IDENTIFICATION; METASTASIS; ANTAGONIST; INHIBITOR; AGENTS; LEVEL;
D O I
10.1016/j.bmc.2011.12.052
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expression of the chemokine receptor CXCR4 in tumors is associated with tumor aggressiveness and poor prognosis for the patient and contributes to metastatic seeding. Therefore it is of high interest to find a specific PET tracer for the imaging of CXCR4 expression in tumors. The aim of this study was the synthesis, Ga-68 labeling and first evaluation of DOTA-4-FBn-TN14003 as a potential PET tracer for this purpose. DOTA-4-FBn-TN14003 was synthesized using solid phase peptide synthesis and radiolabeling of this versatile precursor was performed with (6)8(G)a, which was obtained from a Ge-68/Ga-68 generator. Ga-68-DOTA-4-FBn-TN14003 was reproducibly obtained in isolated radiochemical yields of 72.5 +/- 4.9% with an excellent radiochemical purity of >99.5%. Specific activities of up to 29.8 +/- 3.1 GBq/mu mol were achieved. In competition binding assays with SDF-1 alpha, human T cell lymphoma Jurkat cells expressed high levels of CXCR4 whereas human breast cancer MDA-MB-231 cells expressed significantly lower levels of this chemokine receptor. The inhibition constants (IC50) of Ga-DOTA-4-FBn-TN14003 and 4-FBn-TN14003 to CXCR4 were determined in a competition assay against I-125-SDF-1 alpha using Jurkat as well as MDA-MB-231 cells. The IC50 values of Ga-DOTA-4-FBn-TN14003 (1.99 +/- 0.31 nM) and 4-FBn-TN14003 (4.07 +/- 1.00 nM) proved to be comparable, indicating negligible influence of the metal complex. These results suggest Ga-68-DOTA-4-FBn-TN14003 as a promising agent for the imaging of CXCR4 expression in tumors and metastases. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1502 / 1510
页数:9
相关论文
共 30 条
[1]   Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In vivo Study [J].
Baeuerle, Tobias ;
Merz, Maximilian ;
Komljenovic, Dorde ;
Zwick, Stefan ;
Semmler, Wolfhard .
CLINICAL CANCER RESEARCH, 2010, 16 (12) :3215-3225
[2]  
Chan W., 1999, Fmoc solid phase peptide synthesis: a practical approach
[3]   High Chemokine Receptor CXCR4 Level in Triple Negative Breast Cancer Specimens Predicts Poor Clinical Outcome [J].
Chu, Quyen D. ;
Panu, Lori ;
Holm, Neal T. ;
Li, Benjamin D. L. ;
Johnson, Lester W. ;
Zhang, Songlin .
JOURNAL OF SURGICAL RESEARCH, 2010, 159 (02) :689-695
[4]   Imaging CXCR4 Expression in Human Cancer Xenografts: Evaluation of Monocyclam 64Cu-AMD3465 [J].
De Silva, Ravindra A. ;
Peyre, Kevin ;
Pullambhatla, Mrudula ;
Fox, James J. ;
Pomper, Martin G. ;
Nimmagadda, Sridhar .
JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (06) :986-993
[5]  
Decay Radiation Search, 2011, DECAY RAD SEARCH
[6]   Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors [J].
Hanaoka, Hirofumi ;
Mukai, Takahiro ;
Tamamura, Hirokazu ;
Mori, Tomohiko ;
Ishino, Seigo ;
Ogawa, Kazuma ;
Iida, Yasuhiko ;
Doi, Ryuichiro ;
Fujii, Nobutaka ;
Saji, Hideo .
NUCLEAR MEDICINE AND BIOLOGY, 2006, 33 (04) :489-494
[7]  
Hesselgesser J, 1998, J IMMUNOL, V160, P877
[8]  
Huang EH, 2009, J SURG RES, V155, P231, DOI 10.1016/j.jss.2008.06.044
[9]   PET imaging of CXCR4 using copper-64 labeled peptide antagonist [J].
Jacobson, Orit ;
Weiss, Ido D. ;
Szajek, Lawrence P. ;
Niu, Gang ;
Ma, Ying ;
Kiesewetter, Dale O. ;
Farber, Joshua M. ;
Chen, Xiaoyuan .
THERANOSTICS, 2011, 1 :251-262
[10]  
Jacobson O, 2010, J NUCL MED, V51, P1796, DOI 10.2967/jnumed.110.079418